Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
A total of 2539 adult patients with either BMI 30 or BMI 27 with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, or CVD) were randomized (1:1:1:1) to receive a weekly subcutaneous dose of tirzepatide 5 mg, 10 mg, 15 mg, or a matching placebo
Key findings at the highest dose (12mg weekly): Up to 24% mean body weight reduction over 48 weeks Significant reductions in fasting glucose and insulin resistance markers Meaningful reductions in liver fat content, relevant for participants with metabolic-associated fatty liver disease Once-weekly subcutaneous dosing was generally well-tolerated For context, semaglutide at its approved dose achieves approximately 1517% body weight reduction over 68 weeks
At Preferred Dermatology, we use these injections to help patients feel satisfied with smaller portions, which naturally reduces overall calorie intake
Principales efectos adversos a vigilar (con evidencia cientfica) 1
.jpg)